Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-cash Items (2016 - 2022)

Ani Pharmaceuticals' Non-cash Items history spans 8 years, with the latest figure at $3.2 million for Q4 2022.

  • For Q4 2022, Non-cash Items fell 52.84% year-over-year to $3.2 million; the TTM value through Dec 2022 reached $3.2 million, down 52.84%, while the annual FY2022 figure was $3.2 million, 52.84% down from the prior year.
  • Non-cash Items for Q4 2022 was $3.2 million at Ani Pharmaceuticals, down from $6.8 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $6.8 million in Q4 2021 and bottomed at $372000.0 in Q4 2020.
  • The 5-year median for Non-cash Items is $3.2 million (2022), against an average of $3.9 million.
  • The largest annual shift saw Non-cash Items crashed 94.5% in 2020 before it skyrocketed 1724.19% in 2021.
  • A 5-year view of Non-cash Items shows it stood at $2.2 million in 2018, then soared by 204.41% to $6.8 million in 2019, then plummeted by 94.5% to $372000.0 in 2020, then surged by 1724.19% to $6.8 million in 2021, then crashed by 52.84% to $3.2 million in 2022.
  • Per Business Quant, the three most recent readings for ANIP's Non-cash Items are $3.2 million (Q4 2022), $6.8 million (Q4 2021), and $372000.0 (Q4 2020).